Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations, starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis (NASH), cirrhosis or even hepatocellular carcinoma. NAFLD is a major health burden, and its incidence is increasing worldwide...
Objective The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cirrhosis is often underestimated in healthcare and administrative databases that define disease burden using International Classification of Diseases (ICD) codes. This retrospective audit was ...
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. presentations and discussions at a Single Topic Conference held September 20-22, 2002, and sponsored by the American Association for the Study of Liver ... BA Neuschwander‐Tetri,SH Caldwell - 《Hepatology》 被引量: 3339...
Nonalcoholic steatohepatitis: A study of 49 patients - ScienceDirectnonalcoholic steatohepatitisfatty liver hepatitisalcoholic liver diseasesteatohepatitis... Randall G. Lee MD - 《Human Pathology》 被引量: 2433发表: 1989年 Non-alcoholic Steatohepatitis in Children - ScienceDirect Non-alcoholic steatohepati...
NASH(non-alcoholic steatohepatitis),即非酒精性脂肪性肝炎,是由肝脏中脂肪堆积引起的肝脏疾病和炎症。根据流行病学数据,全球酒精性脂肪肝病(non-alcoholic fatty liver disease,NAFLD)发病率约25%,这些患者约有10-20%的可能进展为NASH,全球各地NASH发病率约为1.5%至6.5%,中国约为3.5%(即目前美国NASH患者人数约为...
2023年4月9日,安徽医科大学/南京医科大学孙倍成团队在Journal of Hepatology(If=30)在线发表了题为“A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis”的研究论文,该研究发现在人类NASH中,Miz1的含量在肝细胞中减少。Miz1被证明与过氧化物还蛋白6...
CPM counts-per-million, DSF disulfiram, 7α-HSDH hydroxysteroid dehydrogenases, BSH bile salt hydrolase, NASH nonalcoholic steatohepatitis. Source data are provided as a Source Data file. Full size image DSF depends on bile acid-induced hepatic farnesoid X receptor (FXR) signaling activation to ...
Non-alcoholic steatohepatitis: new insights from OMICS studies. Non- alcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 2012;13:726-35.Martel, C.; Esposti, D.D.; Bouchet, A.; ... C Martel,DD Esposti,A Bouchet,... - 《Curr Pharm Biotechnol》 被引量: 65...
Nonalcoholic steatohepatitis (NASH), unlike simple steatosis, is a potentially progressive disease. Various types of drugs have been explored for the treatment of NASH. We reviewed the various therapies available, with particular emphasis on their efficacy for the improvement of hepatic fibrosis. Treatm...
Metabolic dysfunction-associated steatohepatitis (MASH): This used to be known as nonalcoholic steatohepatitis (NASH). It's the advanced stage of FLD and means you have inflammation in your liver. The inflammation and liver cell damage that happen with MASH can cause serious problems such as hepa...